Acute Myeloid Leukemia: Evolving Through Targeted Therapies

home / peer-exchange / acute-myeloid-leukemia-evolving-through-targeted-therapies
FLT3 Genetic Alterations in AML

EP. 1: FLT3 Genetic Alterations in AML

July 20th 2020
FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

EP. 2: FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

July 20th 2020
FLT3-Mutated AML: Midostaurin and Chemotherapy

EP. 3: FLT3-Mutated AML: Midostaurin and Chemotherapy

July 20th 2020
Second-Generation FLT3 Inhibitors in AML

EP. 4: Second-Generation FLT3 Inhibitors in AML

July 20th 2020
Utilization of Second-Generation FLT3 Inhibitors in AML

EP. 5: Utilization of Second-Generation FLT3 Inhibitors in AML

July 20th 2020
VIALE Studies in AML

EP. 6: VIALE Studies in AML

July 20th 2020
Optimal Use of Venetoclax in AML

EP. 7: Optimal Use of Venetoclax in AML

July 20th 2020
Venetoclax in AML: Safety Profile

EP. 8: Venetoclax in AML: Safety Profile

July 20th 2020
Monitoring Response to Venetoclax Regimens in AML

EP. 9: Monitoring Response to Venetoclax Regimens in AML

July 20th 2020
FLT3 Triplet Regimens for AML

EP. 10: FLT3 Triplet Regimens for AML

July 20th 2020
IDH Mutations in AML

EP. 11: IDH Mutations in AML

July 20th 2020
IDH1/2 Inhibitors for AML

EP. 12: IDH1/2 Inhibitors for AML

July 20th 2020
IDH Inhibitors and MDS

EP. 13: IDH Inhibitors and MDS

July 20th 2020
Differentiation Syndrome and IDH Inhibitors in AML

EP. 14: Differentiation Syndrome and IDH Inhibitors in AML

July 20th 2020
CPX-351 in Newly Diagnosed Secondary AML

EP. 15: CPX-351 in Newly Diagnosed Secondary AML

July 20th 2020
Gemtuzumab for AML

EP. 16: Gemtuzumab for AML

July 20th 2020
CC-486 Maintenance Therapy in AML

EP. 17: CC-486 Maintenance Therapy in AML

July 20th 2020
Implications for Treating AML With CC-486

EP. 18: Implications for Treating AML With CC-486

July 20th 2020
Progress in the Treatment of AML

EP. 19: Progress in the Treatment of AML

July 20th 2020